Anzeige
Mehr »
Login
Dienstag, 23.07.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
FDA-Genehmigung könnte die 60-Milliarden-Dollar-Chance für diese Aktie entfesseln
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XEH4 | ISIN: FR0011716265 | Ticker-Symbol: 74C
Frankfurt
22.07.24
08:11 Uhr
1,756 Euro
-0,064
-3,52 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CROSSJECT SA Chart 1 Jahr
5-Tage-Chart
CROSSJECT SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,7522,00022.07.

Aktuelle News zur CROSSJECT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCrossject achieves key ZEPIZURE manufacturing milestone51Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
► Artikel lesen
15.07.Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference1
10.07.Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine54Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies...
► Artikel lesen
26.06.Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study98Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine...
► Artikel lesen
12.06.Crossject appoints Dan Chiche, MD as Chief Medical Officer North America132Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes...
► Artikel lesen
04.06.Crossject announces highly successful closing of its €8 million rights offering4
30.05.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy1
14.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024443Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital...
► Artikel lesen
02.05.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe1
25.04.Crossject reports audited financial results for 202389Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free...
► Artikel lesen
08.04.XFRA 74C: WIEDERAUFNAHME/RESUMPTION159FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
02.04.Crossject trading on Euronext to resume as usual on Wednesday April 31
02.04.Crossject Société Anonyme reports FY results1
02.04.Crossject advances in its U.S. Strategy and reports Financial Results for 2023206Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®...
► Artikel lesen
02.04.XFRA 74C: AUSSETZUNG/SUSPENSION92DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCROSSJECT SA EO...
► Artikel lesen
08.03.Crossject gender equality score reaches 96/100 in 20241
27.02.Crossject obtains a financing up to €12 million, in two tranches248Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares...
► Artikel lesen
06.02.Crossject provides strategic update on priorities for 2024221Focusing on regulatory filings and accelerating U.S. commercialization efforts Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance Dijon, France February 6, 2024 -530...
► Artikel lesen
01.02.Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET2
04.01.Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE439Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1